An opportunity to participate in a new clinical trial that will be conducted through the Clinical Trials Network (CTN) of the National Institute on Drug Abuse titled Rural Expansion of Medication Treatment for Opioid Use Disorder: Randomized Controlled Pilot Trial of Extended-Release Buprenorphine vs. Sublingual Buprenorphine-naloxone in Rural Settings (also known as CTN-0102-XR). This study is led by Yih-Ing Hser, PhD, and Larissa Mooney, MD, of the Greater Southern California Node at the University of California, Los Angeles (UCLA).
The purpose of this pilot study is to explore the feasibility, acceptability, and effectiveness of the most recent formulation of injectable extended-release buprenorphine (XR-BUP; CAM2038) for the treatment of opioid use disorder (OUD) in rural settings, as compared to sublingual buprenorphine-naloxone (SL-BUP).
We would appreciate if you can help distribute the study information or identify potential clinics that may be interested in participating the study. Clinic sites need to complete the Site Interest Survey and submit it to the Lead Project Director, Dr. Sherry Larkins at RuralMOUD@mednet.ucla.edu by close of business on January 31, 2023. Following receipt of the Site Interest Survey, the study team may reach out to discuss potential participation of your site.
Please note, the study team will hold drop-in study information sessions on January 17th and 20th for those interested in learning more about the pilot study. Additional details about the drop-in study information sessions will be circulated closer to the meeting dates. In the meantime, please direct questions to the Project Director, Dr. Sherry Larkins at RuralMOUD@mednet.ucla.edu.
The CTN-0102-XR drop-in study information sessions are scheduled for January 17th @ 1pm PST and 20th @ 9am PST.